Publications & Reports

LFA-1 and ICAM-1 antibody-idarubicin conjugates separately prolong murine cardiac allograft survival.

Pietersz GA, Sandrin MS, Ling S, Li YQ, McKenzie IFC
The Austin Research Institute, Heidelberg, Victoria, Australia. g.pietersz@ari.unimelb.edu.au

Abstract

Drug antibody conjugates can enhance the activity of monoclonal antibodies (MoAb) and idarubicin-MoAb conjugates have led to tolerance induction with antibodies which are inactive when used alone. It has been reported that, in mice, antibodies to ICAM-1 and LFA-1 have to be used together to induce tolerance to cardiac allografts; here we show that these monoclonal antibodies, conjugated to idarubicin, can lead to tolerance induction to cardiac allografts when used alone.

Publication

  • Journal: Transplant Immunology
  • Published: 01/10/2001
  • Volume: 9
  • Issue: 1
  • Pagination: 7-11